X

Rubriques :

Maroc - FINANCIALPOST.COM - A La Une - 15/Sep 10:08

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeting medicine and is an inclusion criterion for ongoing trials BOSTON, Sept. 15, 2024 (GLOBE NEWSWIRE) — Precede Biosciences, a […]

Articles similaires

Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

mountaintoday.in - 15/Sep 07:17

Interstitial Lung Disease Clinical Trials Interstitial Lung Disease companies are AstraZeneca, CSL Behring, Syndax Pharmaceuticals, Taiho...

Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

healthtechzone.com - 14/Sep 07:00

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

healthtechzone.com - 05/Sep 12:00

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

healthtechzone.com - 05/Sep 12:00

Les derniers communiqués

Four Seasons to Expand Saudi Arabian Portfolio Alongside Dar Al Omran Company with New Hotel in Madinah
Four Seasons Hotels and Resorts - 07/05/2024
Four Seasons Yachts Unveils Inaugural Itineraries to the Caribbean and Mediterranean and a First Look at its 95 Spectacular Suites
Four Seasons Hotels and Resorts - 27/03/2024
Visual 01Elevating Excellence: Four Seasons Embarks on the Next Stage of Strategic Global Growth
Four Seasons Hotels and Resorts - 22/01/2024

Rubriques :

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Articles similaires

Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

Targeted cancer therapies: Getting radioactive atoms to accumulate in tumours

Targeted cancer therapies: Getting radioactive atoms to accumulate in tumours

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

CAR T-Cell Therapy: FDA Warning on Secondary Cancer Risks

Les derniers communiqués